Drugs / ARCT-021
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05037097 | Aug 2021 → Dec 2023 | COVID-19 | Arcturus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04480957 | Aug 2020 → Jan 2021 | Orthocoronavirinae infectious disease | Arcturus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07390968 | Sep 2026 → Sep 2028 expected | hematopoietic and lymphoid system neoplasm | Fred Hutchinson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04668339 | Jan 2021 → Mar 2022 | COVID-19 | Arcturus Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04728347 | Jan → Dec 2021 | COVID-19 | Arcturus Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARCT-021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05037097 ↗ |
| Modality | Messenger RNA (mRNA) | “ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA” NCT04480957 ↗ |
| Route | Intramuscular | “Study drug (ARCT-021 or control) will be administered as an intramuscular (IM) injection.” NCT04480957 ↗ |